NTP-CANDESARTAN TABLET

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

CANDESARTAN CILEXETIL

Prieinama:

TEVA CANADA LIMITED

ATC kodas:

C09CA06

INN (Tarptautinis Pavadinimas):

CANDESARTAN

Dozė:

32MG

Vaisto forma:

TABLET

Sudėtis:

CANDESARTAN CILEXETIL 32MG

Vartojimo būdas:

ORAL

Vienetai pakuotėje:

30

Recepto tipas:

Prescription

Gydymo sritis:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Produkto santrauka:

Active ingredient group (AIG) number: 0135220004; AHFS:

Autorizacija statusas:

CANCELLED PRE MARKET

Leidimo data:

2015-08-06

Prekės savybės

PRODUCT MONOGRAPH
PR
NTP-CANDESARTAN
(Candesartan cilexetil)
8 mg, 16 mg, 32 mg Tablets
Angiotensin II AT
1
Receptor Blocker
Teva Canada Ltd.
30 Novopharm Court
Toronto, Ontario
M1B 2K9
Control No. 165862
Date of Preparation:
July 12, 2013
2
TABLE OF CONTENTS
PART I:
HEALTH PROFESSIONAL
INFORMATION................................................. 3
SUMMARY PRODUCT INFORMATION
........................................................ 3
INDICATIONS AND CLINICAL USE
.............................................................. 3
CONTRAINDICATIONS
....................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................. 4
ADVERSE REACTIONS
.....................................................................................
6
DRUG INTERACTIONS
...................................................................................
10
DOSAGE AND ADMINISTRATION
.............................................................. 11
OVERDOSAGE
..................................................................................................
13
ACTION AND CLINICAL PHARMACOLOGY
........................................... 14
STORAGE AND
STABILITY...........................................................................
16
DOSAGE FORMS, COMPOSITION AND PACKAGING ........................... 16
PART II:
SCIENTIFIC INFORMATION
........................................................................
17
CLINICAL TRIALS
...........................................................................................
18
DETAILED PHARMACOLOGY
.....................................................................
20
TOXICOLOGY
..................................................................................................
21
REFERENCES
....................................................................................................
24
PART III
CONSUMER INFORMATION
........................................................................
26
3